vs
Koppers Holdings Inc.（KOP）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Koppers Holdings Inc.的1.8倍（$772.1M vs $432.7M），Revvity净利率更高（12.7% vs 6.9%，领先5.9%），Revvity同比增速更快（5.9% vs -9.3%），Revvity自由现金流更多（$161.8M vs $28.5M），过去两年Revvity的营收复合增速更高（9.0% vs -6.7%）
科佩斯控股是一家全球性化工与材料企业，总部位于美国宾夕法尼亚州匹兹堡，入驻建于1920年代的装饰艺术风格摩天大楼科佩斯大厦，在全球范围内开展相关业务经营。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
KOP vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.8倍
$432.7M
营收增速更快
RVTY
高出15.1%
-9.3%
净利率更高
RVTY
高出5.9%
6.9%
自由现金流更多
RVTY
多$133.3M
$28.5M
两年增速更快
RVTY
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $432.7M | $772.1M |
| 净利润 | $29.7M | $98.4M |
| 毛利率 | 25.6% | — |
| 营业利润率 | 11.5% | 14.5% |
| 净利率 | 6.9% | 12.7% |
| 营收同比 | -9.3% | 5.9% |
| 净利润同比 | 391.2% | 3.9% |
| 每股收益（稀释后） | $1.44 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KOPRVTY
| Q4 25 | $432.7M | $772.1M | ||
| Q3 25 | $485.3M | $698.9M | ||
| Q2 25 | $504.8M | $720.3M | ||
| Q1 25 | $456.5M | $664.8M | ||
| Q4 24 | $477.0M | $729.4M | ||
| Q3 24 | $554.3M | $684.0M | ||
| Q2 24 | $563.2M | $691.7M | ||
| Q1 24 | $497.6M | $649.9M |
净利润KOPRVTY
| Q4 25 | $29.7M | $98.4M | ||
| Q3 25 | $23.8M | $46.7M | ||
| Q2 25 | $16.4M | $53.9M | ||
| Q1 25 | $-13.9M | $42.2M | ||
| Q4 24 | $-10.2M | $94.6M | ||
| Q3 24 | $22.8M | $94.4M | ||
| Q2 24 | $26.8M | $55.4M | ||
| Q1 24 | $13.0M | $26.0M |
毛利率KOPRVTY
| Q4 25 | 25.6% | — | ||
| Q3 25 | 24.1% | 53.6% | ||
| Q2 25 | 22.6% | 54.5% | ||
| Q1 25 | 23.2% | 56.5% | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | 21.9% | 56.3% | ||
| Q2 24 | 21.6% | 55.7% | ||
| Q1 24 | 19.3% | 54.6% |
营业利润率KOPRVTY
| Q4 25 | 11.5% | 14.5% | ||
| Q3 25 | 10.7% | 11.7% | ||
| Q2 25 | 7.7% | 12.6% | ||
| Q1 25 | 5.9% | 10.9% | ||
| Q4 24 | 1.3% | 16.3% | ||
| Q3 24 | 9.0% | 14.3% | ||
| Q2 24 | 10.2% | 12.4% | ||
| Q1 24 | 7.0% | 6.8% |
净利率KOPRVTY
| Q4 25 | 6.9% | 12.7% | ||
| Q3 25 | 4.9% | 6.7% | ||
| Q2 25 | 3.2% | 7.5% | ||
| Q1 25 | -3.0% | 6.4% | ||
| Q4 24 | -2.1% | 13.0% | ||
| Q3 24 | 4.1% | 13.8% | ||
| Q2 24 | 4.8% | 8.0% | ||
| Q1 24 | 2.6% | 4.0% |
每股收益（稀释后）KOPRVTY
| Q4 25 | $1.44 | $0.86 | ||
| Q3 25 | $1.17 | $0.40 | ||
| Q2 25 | $0.81 | $0.46 | ||
| Q1 25 | $-0.68 | $0.35 | ||
| Q4 24 | $-0.47 | $0.77 | ||
| Q3 24 | $1.09 | $0.77 | ||
| Q2 24 | $1.25 | $0.45 | ||
| Q1 24 | $0.59 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $928.3M | — |
| 股东权益账面价值 | $574.0M | $7.3B |
| 总资产 | $1.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.62× | — |
8季度趋势，按日历期对齐
现金及短期投资KOPRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务KOPRVTY
| Q4 25 | $928.3M | — | ||
| Q3 25 | $932.9M | — | ||
| Q2 25 | $977.5M | — | ||
| Q1 25 | $989.0M | — | ||
| Q4 24 | $939.5M | — | ||
| Q3 24 | $989.4M | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $877.6M | — |
股东权益KOPRVTY
| Q4 25 | $574.0M | $7.3B | ||
| Q3 25 | $545.6M | $7.4B | ||
| Q2 25 | $526.8M | $7.6B | ||
| Q1 25 | $498.0M | $7.6B | ||
| Q4 24 | $488.7M | $7.7B | ||
| Q3 24 | $532.3M | $7.9B | ||
| Q2 24 | $509.2M | $7.9B | ||
| Q1 24 | $505.8M | $7.8B |
总资产KOPRVTY
| Q4 25 | $1.9B | $12.2B | ||
| Q3 25 | $1.9B | $12.1B | ||
| Q2 25 | $1.9B | $12.4B | ||
| Q1 25 | $1.9B | $12.4B | ||
| Q4 24 | $1.9B | $12.4B | ||
| Q3 24 | $2.0B | $12.8B | ||
| Q2 24 | $1.9B | $13.4B | ||
| Q1 24 | $1.8B | $13.4B |
负债/权益比KOPRVTY
| Q4 25 | 1.62× | — | ||
| Q3 25 | 1.71× | — | ||
| Q2 25 | 1.86× | — | ||
| Q1 25 | 1.99× | — | ||
| Q4 24 | 1.92× | — | ||
| Q3 24 | 1.86× | — | ||
| Q2 24 | 1.97× | — | ||
| Q1 24 | 1.74× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $28.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.6% | 21.0% |
| 资本支出强度资本支出/营收 | 3.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.52× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $67.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流KOPRVTY
| Q4 25 | $45.1M | $182.0M | ||
| Q3 25 | $49.6M | $138.5M | ||
| Q2 25 | $50.5M | $134.3M | ||
| Q1 25 | $-22.7M | $128.2M | ||
| Q4 24 | $74.7M | $174.2M | ||
| Q3 24 | $29.8M | $147.9M | ||
| Q2 24 | $27.2M | $158.6M | ||
| Q1 24 | $-12.3M | $147.6M |
自由现金流KOPRVTY
| Q4 25 | $28.5M | $161.8M | ||
| Q3 25 | $37.6M | $120.0M | ||
| Q2 25 | $38.4M | $115.5M | ||
| Q1 25 | $-37.0M | $112.2M | ||
| Q4 24 | $56.1M | $149.8M | ||
| Q3 24 | $14.4M | $125.6M | ||
| Q2 24 | $10.1M | $136.6M | ||
| Q1 24 | $-38.6M | $129.7M |
自由现金流率KOPRVTY
| Q4 25 | 6.6% | 21.0% | ||
| Q3 25 | 7.7% | 17.2% | ||
| Q2 25 | 7.6% | 16.0% | ||
| Q1 25 | -8.1% | 16.9% | ||
| Q4 24 | 11.8% | 20.5% | ||
| Q3 24 | 2.6% | 18.4% | ||
| Q2 24 | 1.8% | 19.7% | ||
| Q1 24 | -7.8% | 20.0% |
资本支出强度KOPRVTY
| Q4 25 | 3.8% | 2.6% | ||
| Q3 25 | 2.5% | 2.6% | ||
| Q2 25 | 2.4% | 2.6% | ||
| Q1 25 | 3.1% | 2.4% | ||
| Q4 24 | 3.9% | 3.4% | ||
| Q3 24 | 2.8% | 3.3% | ||
| Q2 24 | 3.0% | 3.2% | ||
| Q1 24 | 5.3% | 2.7% |
现金转化率KOPRVTY
| Q4 25 | 1.52× | 1.85× | ||
| Q3 25 | 2.08× | 2.97× | ||
| Q2 25 | 3.08× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 1.31× | 1.57× | ||
| Q2 24 | 1.01× | 2.87× | ||
| Q1 24 | -0.95× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KOP
| Other | $127.8M | 30% |
| Railroad Treated Products | $119.0M | 28% |
| Utility Poles | $79.8M | 18% |
| Pitch And Related Products | $74.1M | 17% |
| Carbon Black Feedstock And Distillates | $14.4M | 3% |
| Railroad Infrastructure Products And Services | $9.9M | 2% |
| Phthalic Anhydride Naphthalene And Other Chemicals | $7.7M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
